ERIS Eris Lifesciences Q3 FY26 results (Oct–Dec 2025) and concall
Eris Lifesciences delivered a robust Q3 FY26, marked by strong growth in Domestic Branded Formulations and a significant surge in its international business, achieving key market share milestones in Insulin. Consolidated PAT saw substantial growth, bolstered by reduced finance costs and tax rates. The company is poised for the launch of Semaglutide following regulatory approval for its partner. However, it faces challenges with lower cash flow conversion and a lagging OAD portfolio, while strategically optimizing its product mix by discontinuing non-core brands.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 21.3%, net profit up 50.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 400 | 405 | 579 | 650 | 315 −21% |
| EBITDA | 100 | 121 | 216 | 297 | 77 −23% |
| Net profit | 2 | 30 | 100 | 150 | 3 +50% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
